BioSpace News Archive

Pulmonary Fibrosis Foundation National Awareness Survey Reveals Little Understanding of Disease in Advance of Rare Disease Week

CENTER VALLEY, Pa. , and BOULDER, Colo. , Feb. 24, 2020 /PRNewswire/ -- Olympus Corporation of the Americas and Amplifire today announced a partnership to improve patient safety with a new digital learning platform designed to improve duodenoscope reprocessing by technicians. The new digital learning platform will be specifically designed for reprocessing the Olympus TJF-Q180

PLEASANTON, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced a broad range of new products at the Advances in Genome Biology and Technology (AGBT) General Meeting, as well as new capabilities for existing products. Today’s announcements further 10x Genomics’ commitment to helping researchers see biology at greater resolution and scale, conduct more simultaneous measurements, and have richer context for their work regardless of the size or location

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 2, 2020, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2019. To access the live conference call by phone, please dial 877-407-0792 (dome

New law gives patients equal access to cancer clinical trials and helps improve minority participation

Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the appointment of Julie Speed to the position of Chief Commercial Officer.

The Canada Health Act provides the critical foundation for the Canadian health care system—a system that is a source of pride for Canadians.

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. to its Board of Directors. Ms. Ali-Jackson will be a member of the Board’s audit committee. “We are very pleased to welcome Kamil to the Board of Directors and look forward to her insights a

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ multimodality multiplex Extended Serological Disease Screening (SDS) Microarray confirming feasibility of the MosaiQ system to address the needs of the Company’s donor center customers for serological disease screening.